A new trading day began on Friday, with MoonLake Immunotherapeutics (NASDAQ: MLTX) stock price up 28.94% from the previous day of trading, before settling in for the closing price of $14.34. MLTX’s price has ranged from $5.95 to $62.75 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -319.65% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -89.57%. With a float of $63.49 million, this company’s outstanding shares have now reached $63.70 million.
MoonLake Immunotherapeutics (MLTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of MoonLake Immunotherapeutics is 10.39%, while institutional ownership is 60.07%. The most recent insider transaction that took place on Dec 08 ’25, was worth 1,960,400. In this transaction Chief Executive Officer of this company sold 130,000 shares at a rate of $15.08, taking the stock ownership to the 2,948,577 shares. Before that another transaction happened on Dec 09 ’25, when Company’s Chief Executive Officer sold 70,000 for $14.49, making the entire transaction worth $1,014,300. This insider now owns 2,878,577 shares in total.
MoonLake Immunotherapeutics (MLTX) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.72 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -89.57% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -21.79% during the next five years compared to -319.65% drop over the previous five years of trading.
MoonLake Immunotherapeutics (NASDAQ: MLTX) Trading Performance Indicators
Here are MoonLake Immunotherapeutics’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.33, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -3.62 in one year’s time.
